Low - dose donor CD8 + cells in the CD4 - depleted graft prevent allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in
first chronic phase.
Not exact matches
«Although TKIs such as the
first - generation TKI imatinib mesylate (IM) and the second - generation TKIs dasatinib and nilotinib have markedly improved the prognosis of patients with
chronic phase CML, a cure remains elusive.
The
first phase involved consultation with Aboriginal people with
chronic illness and experiencing depression, anxiety or a related disorder (the client group), and with service providers who assisted the client group.